Finance Watch: Ten IPOs In Three Days Raise $1.9bn

Several SPACs Also Have Gone Public Already This Year

IPO Edition: Sana leads the group with a $587.5m initial public offering, while Immunocore and Bolt follow with $200m-plus IPOs. The 10 newly public companies generated a 43.3% average return on 8 Feb.

Initial public offerings may have gotten off to a slow start with only three IPOs in January, but 10 drug developers went public in the US between 3 and 5 February raising a total of $1.9bn, including the high-profile cell therapy firm Sana Biotechnology, Inc., and more are slated to launch this week.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.